AstraZeneca Results Presentation Deck

What's next in Oncology Solid pipeline moving forward What's next Selected Phase I/II new medicines adavosertib (WEE1) uterine, ovarian cancer oleclumab (CD73) solid tumours AZD4573 (CDK9) blood cancers AZD5991 (MCL1) blood cancers AZD2936 (PD-1/TIGIT) solid tumours AZD5305 (PARP1) solid tumours New in Phase I✔ ceralasertib (ATR) solid tumours, blood cancers MEDI5752 (PD-1/CTLA4) solid tumours AZD2811 (Aurora B) solid tumours, blood cancers AZD0466 (Bcl-2/xL) solid tumours, blood cancers AZD7789 (PD-1/TIM3) solid tumours New in Phase 1 ✓ What's now Phase III new medicines New Phase III datopotamab deruxtecan multiple cancers monalizumab head & neck cancer New Orpathys Phase III NSCLC Tagrisso NSCLC New Phase III Major Phase III lifecycle management New Lynparza Phase III multiple cancers Imfinzi multiple cancers camizestrant breast cancer 20 WEE1 = tyrosine kinase WEE1; CD73 = ecto-5'-nucleotidase; CDK9 = cyclin-dependent kinase 9 MCL1= induced myeloid leukaemia cell differentiation protein; PD-1 = programmed cell death protein 1; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains; ATR = ataxia telangiectasia and rad3-related kinase; CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; Bcl-2 = B-cell lymphoma 2; TIM3 = T-cell immunoglobulin domain and mucin domain 3. capivasertib breast, prostate cancer tremelimumab multiple cancers Enhertu New Phase III multiple cancers Calquence multiple cancers

View entire presentation